Cazenove Capital Management’s Biogen BIIB Stock Holding History

Cazenove Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$137K	Buy	+638	New	+$136K	0.11%	94

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cazenove Capital Management's BIIB Position: Q2 2013 in Review

Cazenove Capital Management opened a new position in Biogen (BIIB) in Q2 2013: 638 shares worth $137K. The stake represents 0.11% of the portfolio and ranks #94 among its holdings.

646 funds tracked by Wall St. Rank hold BIIB as of Q2 2013.

Cazenove Capital Management held 638 shares of Biogen worth $137K as of Q2 2013.
Biogen was a new Cazenove Capital Management position in Q2 2013.
Biogen made up 0.11% of Cazenove Capital Management's portfolio in Q2 2013, its #94 holding.
646 funds tracked by Wall St. Rank held Biogen as of Q2 2013.

Based on Cazenove Capital Management's 13F filing for Q2 2013, filed 14 Aug 2013.